Baseline clinical characteristics and treatments of the 3 PTCL cohorts
| . | Entire cohort (N = 132) . | CCD cohort (n = 87) . | Prospective cohort (n = 72) . | P . |
|---|---|---|---|---|
| Demographics | ||||
| Median age, y (range) | 65 (25-82) | 63 (26-81) | 66 (25-81) | .87 |
| Male, n (%) | 81 (61) | 56 (64) | 43 (60) | .83 |
| Disease characteristics at diagnosis | ||||
| Histology, n (%) | ||||
| PTCL-NOS | 36 (27) | 28 (32) | 15 (21) | .25 |
| AITL | 62 (47) | 39 (45) | 38 (53) | .59 |
| PTCL-TFH | 9 (7) | 6 (7) | 6 (8) | .92 |
| ALK− ALCL | 15 (11) | 8 (9) | 7 (10) | .88 |
| ALK+ ALCL | 6 (5) | 2 (2) | 2 (3) | .71 |
| MEITL | 4 (3) | 4 (5) | 4 (6) | .65 |
| Stage, n (%) | ||||
| I/II∗ | 22 (17) | 15 (17) | 14 (19) | .90 |
| III/IV∗ | 110 (83) | 72 (83) | 58 (81) | |
| BM involvement by morphological assessment, n (%) | ||||
| No | 72 (55) | 55 (63) | 42 (58) | .99 |
| Yes | 39 (29) | 32 (37) | 23 (32) | |
| Unknown | 21 (16) | 0 (0) | 7 (10) | |
| Extranodal disease other than BM involvement, n (%) | ||||
| No | 81 (61) | 52 (60) | 44 (61) | .98 |
| Yes | 51 (39) | 35 (40) | 28 (39) | |
| LDH elevated, n (%) | ||||
| No | 39 (30) | 34 (39) | 29 (40) | .91 |
| Yes | 58 (44) | 53 (61) | 39 (54) | |
| Unknown | 35 (27) | 0 (0) | 4 (6) | |
| ECOG PS ≥2, n (%) | ||||
| No | 112 (85) | 77 (89) | 62 (86) | .87 |
| Yes | 14 (11) | 10 (11) | 10 (14) | |
| Unknown | 6 (5) | 0 (0) | 0 (0) | |
| IPI score, n (%) | ||||
| 0-1 | 18 (14) | 17 (20) | 14 (19) | .99 |
| 2 | 30 (23) | 28 (32) | 22 (31) | |
| 3 | 31 (24) | 31 (36) | 20 (28) | |
| 4-5 | 15 (11) | 11 (14) | 11 (15) | |
| Incomplete data | 38 (29) | 0 (0) | 5 (7) | |
| PIT score, n (%) | ||||
| 0-1 | 44 (33) | 44 (51) | 30 (42) | .95 |
| 2 | 24 (18) | 24 (28) | 20 (28) | |
| 3-4 | 19 (14) | 19 (22) | 11 (15) | |
| Incomplete data | 45 (34) | 0 (0) | 11 (15) | |
| Treatments | ||||
| Chemotherapy regimen, n (%) | ||||
| CHOEP/EPOCH | 59 (45) | 38 (44) | 31 (43) | .97 |
| CHOP | 40 (30) | 23 (26) | 19 (26) | |
| BV-CH(E)P | 16 (12) | 12 (14) | 11 (15) | |
| CHOP-based + novel agent | 17 (13) | 14 (16) | 11 (15) | |
| ASCT in first remission, n (%) | ||||
| No | 82 (62) | 50 (57) | 39 (54) | .52 |
| Yes | 50 (38) | 37 (43) | 33 (46) | |
| Maintenance therapy, n (%) | ||||
| No | 119 (90) | 75 (86) | 60 (83) | .34 |
| Yes | 13 (10) | 12 (14) | 12 (17) | |
| . | Entire cohort (N = 132) . | CCD cohort (n = 87) . | Prospective cohort (n = 72) . | P . |
|---|---|---|---|---|
| Demographics | ||||
| Median age, y (range) | 65 (25-82) | 63 (26-81) | 66 (25-81) | .87 |
| Male, n (%) | 81 (61) | 56 (64) | 43 (60) | .83 |
| Disease characteristics at diagnosis | ||||
| Histology, n (%) | ||||
| PTCL-NOS | 36 (27) | 28 (32) | 15 (21) | .25 |
| AITL | 62 (47) | 39 (45) | 38 (53) | .59 |
| PTCL-TFH | 9 (7) | 6 (7) | 6 (8) | .92 |
| ALK− ALCL | 15 (11) | 8 (9) | 7 (10) | .88 |
| ALK+ ALCL | 6 (5) | 2 (2) | 2 (3) | .71 |
| MEITL | 4 (3) | 4 (5) | 4 (6) | .65 |
| Stage, n (%) | ||||
| I/II∗ | 22 (17) | 15 (17) | 14 (19) | .90 |
| III/IV∗ | 110 (83) | 72 (83) | 58 (81) | |
| BM involvement by morphological assessment, n (%) | ||||
| No | 72 (55) | 55 (63) | 42 (58) | .99 |
| Yes | 39 (29) | 32 (37) | 23 (32) | |
| Unknown | 21 (16) | 0 (0) | 7 (10) | |
| Extranodal disease other than BM involvement, n (%) | ||||
| No | 81 (61) | 52 (60) | 44 (61) | .98 |
| Yes | 51 (39) | 35 (40) | 28 (39) | |
| LDH elevated, n (%) | ||||
| No | 39 (30) | 34 (39) | 29 (40) | .91 |
| Yes | 58 (44) | 53 (61) | 39 (54) | |
| Unknown | 35 (27) | 0 (0) | 4 (6) | |
| ECOG PS ≥2, n (%) | ||||
| No | 112 (85) | 77 (89) | 62 (86) | .87 |
| Yes | 14 (11) | 10 (11) | 10 (14) | |
| Unknown | 6 (5) | 0 (0) | 0 (0) | |
| IPI score, n (%) | ||||
| 0-1 | 18 (14) | 17 (20) | 14 (19) | .99 |
| 2 | 30 (23) | 28 (32) | 22 (31) | |
| 3 | 31 (24) | 31 (36) | 20 (28) | |
| 4-5 | 15 (11) | 11 (14) | 11 (15) | |
| Incomplete data | 38 (29) | 0 (0) | 5 (7) | |
| PIT score, n (%) | ||||
| 0-1 | 44 (33) | 44 (51) | 30 (42) | .95 |
| 2 | 24 (18) | 24 (28) | 20 (28) | |
| 3-4 | 19 (14) | 19 (22) | 11 (15) | |
| Incomplete data | 45 (34) | 0 (0) | 11 (15) | |
| Treatments | ||||
| Chemotherapy regimen, n (%) | ||||
| CHOEP/EPOCH | 59 (45) | 38 (44) | 31 (43) | .97 |
| CHOP | 40 (30) | 23 (26) | 19 (26) | |
| BV-CH(E)P | 16 (12) | 12 (14) | 11 (15) | |
| CHOP-based + novel agent | 17 (13) | 14 (16) | 11 (15) | |
| ASCT in first remission, n (%) | ||||
| No | 82 (62) | 50 (57) | 39 (54) | .52 |
| Yes | 50 (38) | 37 (43) | 33 (46) | |
| Maintenance therapy, n (%) | ||||
| No | 119 (90) | 75 (86) | 60 (83) | .34 |
| Yes | 13 (10) | 12 (14) | 12 (17) | |
BV-CH(E)P, CHOP with brentuximab vedotin in place of vincristine with or without etoposide; CHOEP, CHOP with etoposide; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.
One patient with documented stage II disease and 8 patients with documented stage III disease based on imaging were missing baseline BM biopsies.